Submit a project
0 results

Our flagship strategy

We invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives.

Capital X, the 10th iteration of our flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.

CloseFundAMT
2008Sofinnova Capital VI€260 million
2012Sofinnova Capital VII€240 million
2015Sofinnova Capital VIII€300 million
2018Sofinnova Capital IX€333 million
2021Sofinnova Capital X€472 million

  • Close: 2008

    Fund: Sofinnova Capital VI

    AMT: €260 million

  • Close: 2012

    Fund: Sofinnova Capital VII

    AMT: €240 million

  • Close: 2015

    Fund: Sofinnova Capital VIII

    AMT: €300 million

  • Close: 2018

    Fund: Sofinnova Capital IX

    AMT: €333 million

  • Close: 2021

    Fund: Sofinnova Capital X

    AMT: €472 million

“I've wanted to be in biotech since I was 16 years old. It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”

“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”

Maina Bhaman

Partner, Sofinnova Partners - Capital Strategy

Henrijette Richter

Managing Partner, Sofinnova Partners

The
Team

Companies

Fund iteration
Status
Deal lead

Related News

Join our mailing list

Keep up to date with our latest news.

Required
Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.